Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
15 1월 2026
Two and a half years of the UPC – Trends and turning points
19 12월 2025
Treasury Updates Merger Rules
19 12월 2025
A new era for EU pharmaceutical law: political agreement reached on the reform
19 12월 2025
Preserving the status quo: Boehringer Ingelheim awarded interim injunction
31 10월 2025
High bar for material adverse change in M&A: Lessons from the Mayne Pharma / Cosette decision
18 9월 2025
Are you cyber ready? The cyber challenge through the eyes of Australia’s legal leaders
12 9월 2025
Trump administration moves to rein in direct-to-consumer prescription drug advertising
21 7월 2025
The UPC – Two years on
21 7월 2025
No rest for the caretakers: health care industry in crosshairs for expanded False Claims Act and criminal enforcement activity
30 6월 2025
New merger control regime – What you need to know for dealmaking in Australia
18 6월 2025
Protecting your business: The implications of Australia’s new privacy tort
16 5월 2025
Focus on minimum award rates and addressing gender undervaluation – which sectors are next?
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane